Selgantolimod clinical trials
Also written GS-9688.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses selgantolimod is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Gilead Sciences (3) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Studies
Open first, then newest update. How each study uses selgantolimod is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIVTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05551273Written as SelgantolimodHow we know
- Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)CompletedPhase 2Gilead SciencesNCT04891770Written as SelgantolimodHow we know
- Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on TreatmentCompletedPhase 2Gilead SciencesNCT03615066Written as SelgantolimodHow we know
- Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis BCompletedPhase 2Gilead SciencesNCT03491553Written as SelgantolimodHow we know
What changed recently
From the registry's own updates since Oct 23, 2026.
Results posted1
Stopped1
- Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIVTerminatedNov 17, 2026NCT05551273
Codes
What other systems call selgantolimod · ClinicalTrials.gg INT001505
- MeSH (NLM) C000712275selgantolimodConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) RM4GJT3SMQSELGANTOLIMODConfirmed FDA, NLM
- NCI Thesaurus C170376SelgantolimodOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000712275 | selgantolimod | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | RM4GJT3SMQ | SELGANTOLIMOD | Confirmed FDA, NLM |
| NCI Thesaurus | C170376 | Selgantolimod | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.